Q-omics provides the consensus-scored MAP4K3-DT profile across patient tissues and cancer cell-line models. MAP4K3-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAP4K3-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MAP4K3-DT RNA expression shows 19,768 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where MAP4K3-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP4K3-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP4K3-DT survival associations across molecular data types. MAP4K3-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP4K3-DT RNA expression–survival associations across cancer types. High MAP4K3-DT expression shows unfavorable associations in UVM, UCEC, HNSC, CESC and KIRP, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAP4K3-DT RNA expression.
This table summarizes MAP4K3-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAP4K3-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP4K3-DT shows lower tumor expression in KIRC, THCA, KICH, LUSC, KIRP and UCEC. The KIRC box plot shows higher MAP4K3-DT RNA expression in normal versus tumor tissue (log2 FC = −0.592, t-test p < 0.001).
This table shows molecular features associated with MAP4K3-DT in patient tissues and cancer cell lines. In patient samples, MAP4K3-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
